Immunotherapy of osteosarcoma patients with virus-modified tumor cells.
Twelve patients 11-20 years of age with recurrent osteosarcoma were immunized with either autologous or allogeneic tumor cells infected with influenza virus, strain B/Michigan or A/Port Chalmers. Six patients received only the vaccine, and the remaining six patients continued to receive methotrexate chemotherapy. The main objectives of this study were to determine if immunizations were toxic, if antibodies developed to the influenza virus antigen component of the vaccine, if this vaccine increased tumor-specific cellular and humoral immunity, and if the increase in immune response could be correlated with clinical course and prognosis. In all 12 cases, toxicity was negligible, and immunizations boosted antibody titers to both tumor cell and influenza virus antigens. However, in four of the six patients with advanced disease who received immunotherapy only, the vaccine did not stimulate mixed lymphocytes nor did it increase cell-mediated immunity. By contrast, five of six patients with minimal disease who continued methotrexate therapy developed cellular and humoral immunity in response to both allogeneic and autologous tumor cells. Although no clear-cut relationship between responses to the tumor cell vaccine and clinical course and prognosis could be demonstrated, three of the six patients with minimal disease have survived for 7-8 months after the first vaccination, without progression of disease. This study demonstrates that plasma membrane preparations derived from different lines of virus-infected osteosarcoma tumor cells will elicit an antibody response in patients with drug-resistant progressive osteogenic sarcoma.
D000293:Adolescent; D000328:Adult; D000912:Antibodies, Neoplasm / Q000032:analysis; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D001859:Bone Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002460:Cell Line; D002648:Child; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization; D007167:Immunotherapy; D007700:Kinetics; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D009975:Orthomyxoviridae / Q000276:immunology*; D012516:Osteosarcoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014612:Vaccines / Q000009:adverse effects
D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D014612:Vaccines; D008727:Methotrexate